What is NDC 49252-066?

49252-066 is the product NDC for Olmesartan Medoxomil, Olmesartan medoxomil 20 mg/1 tablet, coated, listed with the FDA by Inventia Healthcare Limited. It has 4 package NDCs, shown above in 10- and 11-digit form.

Inventia Healthcare Limited, NDC labeler code 49252. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Olmesartan Medoxomil?

122 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Olmesartan Medoxomil NDC 49252-066

NDC codes

FDA NDC Directory

Product NDC (as listed)49252-066Labeler and product segments. Claims need a package NDC.

Product NDC at billing width49252-0066Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
49252-066-10	4925200661049252006610	30 TABLET, COATED in 1 BOTTLE (49252-066-10)Marketed from May 29, 2020
49252-066-12	4925200661249252006612	90 TABLET, COATED in 1 BOTTLE (49252-066-12)Marketed from May 29, 2020
49252-066-18	4925200661849252006618	1000 TABLET, COATED in 1 BOTTLE (49252-066-18)Marketed from May 29, 2020
49252-066-57	4925200665749252006657	10 CARTON in 1 BLISTER PACK (49252-066-57) / 10 TABLET, COATED in 1 CARTONMarketed from May 29, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Olmesartan Medoxomil
Generic name (nonproprietary): olmesartan medoxomil
Active ingredients: Olmesartan medoxomil — 20 mg/1
Dosage form: Tablet, Coated
Route: Oral
Labeler: Inventia Healthcare LimitedNDC labeler code 49252
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208659
Marketing start: May 29, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Angiotensin 2 Receptor Antagonists (Mechanism)
Identifiers: Product ID 49252-066_f29310d1-7b00-4057-9dd1-d9a69f542d5eSPL ID f29310d1-7b00-4057-9dd1-d9a69f542d5eSPL set ID 05a807bf-5175-43a2-a676-215bba2645a8RxCUI 349373, 349401, 349405UNII 6M97XTV3HDUPC 0349252066106, 0349252065109, 0349252067103
Pharmacologic class: Angiotensin 2 Receptor Blocker

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N449252006610 followed by a unit qualifier and the quantity

Package 49252-0066-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 15, 2023. This label includes a boxed warning.

Indications (excerpt from the label)

Olmesartan medoxomil tablet is indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes ma…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 49252-066

What is NDC 49252-066?: 49252-066 is the product NDC for Olmesartan Medoxomil, Olmesartan medoxomil 20 mg/1 tablet, coated, listed with the FDA by Inventia Healthcare Limited. It has 4 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Olmesartan Medoxomil.
What is the active ingredient?: Olmesartan medoxomil.
Who is the labeler?: Inventia Healthcare Limited, NDC labeler code 49252. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Olmesartan Medoxomil?: 122 other product NDCs are listed under this name. See all Olmesartan Medoxomil NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Olmesartan Medoxomil NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Olmesartan medoxomil	Olmesartan medoxomil 5 mg/1	TabletOral	NorthStar RxLLC	72603-950	72603-0950-0172603-0950-02
Olmesartan medoxomil	Olmesartan medoxomil 20 mg/1	TabletOral	NorthStar RxLLC	72603-951	72603-0951-0172603-0951-02
Olmesartan medoxomil	Olmesartan medoxomil 40 mg/1	TabletOral	NorthStar RxLLC	72603-952	72603-0952-0172603-0952-02
Olmesartan Medoxomil	Olmesartan medoxomil 5 mg/1	Tablet, Film coatedOral	HEC Pharm USA Inc.	72303-0848	72303-0848-0172303-0848-02
Olmesartan Medoxomil	Olmesartan medoxomil 20 mg/1	Tablet, Film coatedOral	HEC Pharm USA Inc.	72303-0849	72303-0849-0172303-0849-02
Olmesartan Medoxomil	Olmesartan medoxomil 40 mg/1	Tablet, Film coatedOral	HEC Pharm USA Inc.	72303-0850	72303-0850-0172303-0850-02
Olmesartan medoxomil	Olmesartan medoxomil 20 mg/1	TabletOral	REMEDYREPACK INC.	70518-4598	70518-4598-00
Olmesartan Medoxomil	Olmesartan medoxomil 40 mg/1	TabletOral	Umedica Laboratories USA Inc.	60290-011	60290-0011-0160290-0011-0260290-0011-03
Olmesartan Medoxomil	Olmesartan medoxomil 5 mg/1	TabletOral	Umedica Laboratories USA Inc.	60290-009	60290-0009-0160290-0009-0260290-0009-03
Olmesartan Medoxomil	Olmesartan medoxomil 20 mg/1	TabletOral	Umedica Laboratories USA Inc.	60290-010	60290-0010-0160290-0010-0260290-0010-03

All 123 Olmesartan Medoxomil NDCs

Other NDCs under ANDA 208659

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208659
Product	Strength	Form · route	Labeler	Product NDC
Olmesartan Medoxomil	Olmesartan medoxomil 5 mg/1	Tablet, CoatedOral	Inventia Healthcare Limited	49252-065
Olmesartan Medoxomil	Olmesartan medoxomil 40 mg/1	Tablet, CoatedOral	Inventia Healthcare Limited	49252-067
Olmesartan Medoxomil	Olmesartan medoxomil 20 mg/1	Tablet, CoatedOral	Rising Pharma Holdings, Inc.	64980-602
Olmesartan Medoxomil	Olmesartan medoxomil 40 mg/1	Tablet, CoatedOral	Rising Pharma Holdings, Inc.	64980-603
Olmesartan Medoxomil	Olmesartan medoxomil 5 mg/1	Tablet, CoatedOral	Rising Pharma Holdings, Inc.	64980-665
Olmesartan Medoxomil	Olmesartan medoxomil 5 mg/1	Tablet, CoatedOral	Bryant Ranch Prepack	71335-2996